Journals / art / 2015 / Cilt: 30 - Sayı: 1

Serum Fetuin-A level in patients with ankylosing spondylitis and its relationship with clinical parameters

Journal
art
Pages
1–5
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further research is required to establish the role of serum fetuin-A levels as a surrogate marker of disease activity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to investigate the association of serum fetuin-A levels with disease activation and clinical parameters in ankylosing spondylitis (AS) patients.
📊
Key Findings & Data:Patients and methods: Forty-seven AS patients (30 males, 17 females; mean age 39.7±11.1 years; range 20 to 69 years) and 30 healthy controls (14 males, 16 females; mean age 42.0±11.5 years; range 19 to 63 years) were included in the study.
💡
Conclusion & Impact:However, further research is required to establish the role of serum fetuin-A levels as a surrogate marker of disease activity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to investigate the association of serum fetuin-A levels with disease activation and clinical parameters in ankylosing spondylitis (AS) patients. Patients and methods: Forty-seven AS patients (30 males, 17 females; mean age 39.7±11.1 years; range 20 to 69 years) and 30 healthy controls (14 males, 16 females; mean age 42.0±11.5 years; range 19 to 63 years) were included in the study. Erythrocyte sedimentation rate, C-reactive protein, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Radiology Index, and Bath Ankylosing Spondylitis Metrology Index were used in the assessment of AS. Serum fetuin-A levels were measured using ELISA. Results: Mean serum fetuin-A values in AS patients (984±203 ng/mL) were significantly lower compared to controls (1156±218 ng/mL) (p=0.001). While a statistically significant negative correlation was detected in AS patients between fetuin-A values and C-reactive protein (p=0.009, r=-0.377), no significant correlation was detected between erythrocyte sedimentation rate, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Functional Index or Bath Ankylosing Spondylitis Radiology Index parameters and fetuin-A. Conclusion: Serum fetuin-A levels in AS patients were lower than the control group. However, further research is required to establish the role of serum fetuin-A levels as a surrogate marker of disease activity.

Özet

Amaç: Bu çalışmada, ankilozan spondilit (AS) hastalarında serum fetüin-A düzeyinin hastalık aktivasyonu ve klinik parametrelerle ilişkisi araştırıldı. Hastalar ve yöntemler: Çalışmaya 47 AS hastası (30 erkek, 17 kadın; ort. yaş 39.7±11.1 yıl; dağılım 20-69 yıl) ve 30 sağlıklı kontrol (14 erkek, 16 kadın; ort. yaş 42.0±11.5 yıl; dağılım 19-63 yıl) alındı. Ankilozan spondilitin değerlendirilmesinde eritrosit sedimentasyon hızı, C-reaktif protein, Bath Ankilozan Spondilit Hastalık Aktivite İndeksi, Bath Ankilozan Spondilit Fonksiyonel İndeksi, Bath Ankilozan Spondilit Radyoloji İndeksi ve Bath Ankilozan Spondilit Metroloji İndeksi kullanıldı. Serum fetüin-A düzeyleri ELISA kullanılarak ölçüldü. Bulgular: Ankilozan spondilit hastalarında ortalama serum fetüin-A değerleri (984±203 ng/mL) kontrollere göre (1156±218 ng/mL) anlamlı şekilde düşüktü (p=0.001). Ankilozan spondilit hastalarında fetüin-A değerleri ile C-reaktif protein arasında istatistiksel olarak anlamlı negatif korelasyon saptanırken (p=0.009, r=-0.377) eritrosit sedimentasyon hızı, Bath Ankilozan Spondilit Hastalık Aktivite İndeksi, Bath Ankilozan Spondilit Metroloji İndeksi, Bath Ankilozan Spondilit Fonksiyonel İndeksi veya Bath Ankilozan Spondilit Radyoloji İndeksi parametreleri ile fetüin-A arasında herhangi bir anlamlı korelasyon saptanmadı. Sonuç: Serum fetüin-A düzeyleri AS hastalarında kontrol grubundan daha düşüktü. Öte yandan, serum fetüin-A düzeylerinin hastalık aktivitesinde temsili bir belirteç olarak rolünü gösteren ileri araştırmalar gerekmektedir.

🔖

Cite This Article

GÖKMEN, F., AKBAL, A., GÜNEŞ, F., BİNNETOĞLU, E., ŞEN, H., AŞIK, M., AKBAL, E., TURKON, H., VURAL, A., KÖMÜR, E. (2015). Serum Fetuin-A level in patients with ankylosing spondylitis and its relationship with clinical parameters. art, Cilt: 30 - Sayı: 1, 1–5. https://ajindex.com/articles/195495

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
  2. Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 1999;26:971-4.
  3. Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/ fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003;278:13333-41.
  4. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-29.
  5. Sato H, Kazama JJ, Wada Y, Kuroda T, Narita I, Gejyo F, et al. Decreased levels of circulating alpha2- Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern Med 2007;46:1685-91.
  6. Kusnierz-Cabala B, Gurda-Duda A, Panek J, Fedak D, Dumnicka P, Solnica B, et al. Serum fetuin A concentrations in patients with acute pancreatitis. Clin Lab 2010;56:191-5
  7. Metry G, Stenvinkel P, Qureshi AR, Carrero JJ, Yilmaz MI, Bárány P, et al. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest 2008;38:804-11.
  8. Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997;95:778-81.
  9. Li W, Zhu S, Li J, Huang Y, Zhou R, Fan X, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 2011;6:16945. Sari I, Kebapcilar L, Taylan A, Bilgir O, Kozaci DL, Yildiz Y, et al. Fetuin-A and interleukin-18 levels in ankylosing spondylitis. Int J Rheum Dis 2010;13:75-81.
  10. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
  11. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
  12. MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998;41:2263-70.
  13. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL,